分子瘤标记物的临床实践指南,第二版综述第1部分
Yoshinori Kikuchi1, Hideaki Shimada2,3, Yutaka Hatanaka4
1Department of Clinical Oncology, Toho University, Tokyo, Japan.
International journal of clinical oncology
|November 29, 2023
概括
本综述介绍了更新的分子瘤标记指南,第二版,反映了癌症诊断和向治疗的进步. 它涵盖了必要的瘤标志物和用于个性化癌症治疗的伴侣诊断.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 基因和蛋白质分析技术的重大进展已经确定了许多潜在的癌症诊断目标.
- 该领域已经从传统的瘤标记物演变为分子向治疗的伴侣标记物.
- 日本分子瘤标记物研究协会自1981年成立以来一直指导着这一发展.
研究的目的:
- 介绍"分子瘤标志物指南"第二版的英语版本的审查 (第一部分).
- 总结各种癌症类型的关键瘤标记物和伴随标记物.
- 提供最新的信息,反映癌症诊断和治疗的最新发展.
主要方法:
- 审查和综合当前文献和临床指导方针.
- 包括使用下一代测序的基因面板测试数据.
- 考虑扩大免疫检查点抑制剂的适用性.
主要成果:
- 分子瘤标记指南的第二版于2021年9月出版.
- 它结合了最近的进展,包括基于下一代测序的基因组测试.
- 这些指导方针涉及分子向疗法和免疫检查点抑制剂的伴随标记的整合.
结论:
- 更新的指导方针对于在不断变化的个性化癌症医学领域进行导航至关重要.
- 它们为临床医生和研究人员提供了关于利用分子标记物用于诊断和治疗的基本信息.
- 这篇英语评论促进了对分子瘤标志物最新知识的更广泛获取.
更多相关视频
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.4K
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
11.9K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
